• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

AB Blood Group is Associated with Cognitive Impairment

September 26, 2014

tx_news_26_septIn a recent case-controlled study published in Neurology, researchers assessed the relationship between ABO blood group, factor VIII, and the incident cognitive impairment.

Compared to blood group O, blood group AB individuals had an increased risk of cognitive decline after adjusting for age, race, religion, and sex (odds ratio=1.82, 95% CI=1.15-2.90) and had higher factor VIII plasma levels. Factor VIII accounted for less than 20% of the association between AB blood group and cognitive impairment. Further studies are needed to define the relationship and underlying mechanisms between cognitive impairment and blood type.

Reference

1. Alexander KS, Zakai NA, Gillett S, McClure LA, Wadley V, Unverzagt F, Cushman M. ABO blood type, factor VIII, and incident cognitive impairment in the REGARDS cohort. Neurology 2014.

Filed Under

  • News
  • Serology/Genotyping

Recommended

  • Final FDA Guidance to Reduce Transfusion-Transmitted Human T-Lymphotropic Virus Types I and II

  • Leukoreduction Alone May Be Sufficient to Prevent Transfusion-Transmitted Cytomegalovirus Infection in Preterm Infants

  • Improving Peripheral Blood Stem Cell Collection for Autologous Stem Cell Transplantation

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Tranexamic Acid for Patients with Hematological Disorders

  • Interventions to Prevent Vasovagal Reactions among Blood Donors

  • Nipocalimab for Severe Hemolytic Disease of the Fetus and Newborn

  • Clinical Guidelines for Anemia and Chronic Kidney Disease

    Question of the Day

    Copyright © 2026 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley